REG - Societe Generale SA Takeda Pharma.Co.Ltd - Form 8.3 - Takeda Pharmaceutical CO LTD
RNS Number : 0700ISociete Generale SA21 November 2018FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser:
Société Générale S.A.
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Takeda Pharmaceutical CO LTD
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
20/11/2018
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES: Shire PLC
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
1,940,819
0.25
8,703,260
1.11
(2) Cash-settled derivatives:
7,818,633
1.00
0
0.00
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
121,500
0.02
125,000
0.02
TOTAL:
9,880,952
1.26
8,828,260
1.13
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchase/sale
Number of securities
Price per unit
JPY
Ordinary
Purchase
200
4423
Ordinary
Purchase
100
4454
Ordinary
Purchase
200
4412
Ordinary
Purchase
200
4393
Ordinary
Purchase
200
4419
Ordinary
Purchase
200
4452
Ordinary
Purchase
100
4419
Ordinary
Purchase
100
4419
Ordinary
Purchase
200
4435
Ordinary
Purchase
200
4434
Ordinary
Purchase
200
4393
Ordinary
Purchase
2,000
4441
Ordinary
Purchase
1,400
4475
Ordinary
Purchase
4,200
4425
Ordinary
Purchase
700
4423
Ordinary
Purchase
1,200
4400
Ordinary
Purchase
2,500
4414
Ordinary
Purchase
300
4442
Ordinary
Purchase
2,200
4440
Ordinary
Purchase
1,900
4426
Ordinary
Purchase
1,400
4461
Ordinary
Purchase
500
4464
Ordinary
Purchase
1,400
4465
Ordinary
Purchase
100
4370
Ordinary
Purchase
100
4371
Ordinary
Purchase
100
4374
Ordinary
Purchase
1,800
4379
Ordinary
Purchase
800
4427
Ordinary
Purchase
100
4434
Ordinary
Purchase
2,500
4424
Ordinary
Purchase
300
4399
Ordinary
Purchase
300
4414
Ordinary
Purchase
2,600
4476
Ordinary
Purchase
100
4443
Ordinary
Purchase
200
4425
Ordinary
Purchase
100
4378
Ordinary
Purchase
600
4386
Ordinary
Purchase
1,800
4370
Ordinary
Purchase
400
4476
Ordinary
Purchase
100
4406
Ordinary
Purchase
100
4406
Ordinary
Purchase
200
4390
Ordinary
Purchase
100
4408.5
Ordinary
Purchase
500
4387
Ordinary
Purchase
300
4391
Ordinary
Purchase
300
4389
Ordinary
Purchase
700
4399
Ordinary
Purchase
100
4400
Ordinary
Purchase
1,100
4393
Ordinary
Purchase
1,100
4403
Ordinary
Purchase
1,100
4403
Ordinary
Purchase
600
4407
Ordinary
Purchase
400
4407
Ordinary
Purchase
200
4402
Ordinary
Purchase
1,100
4414
Ordinary
Purchase
1,000
4419
Ordinary
Purchase
700
4418
Ordinary
Purchase
1,100
4420
Ordinary
Purchase
200
4407
Ordinary
Purchase
100
4405
Ordinary
Purchase
100
4405
Ordinary
Purchase
200
4406
Ordinary
Purchase
300
4400
Ordinary
Purchase
800
4404
Ordinary
Purchase
1,100
4410
Ordinary
Purchase
500
4423
Ordinary
Purchase
1,100
4420
Ordinary
Purchase
200
4375
Ordinary
Purchase
300
4372
Ordinary
Purchase
1,100
4373
Ordinary
Purchase
100
4375
Ordinary
Purchase
500
4380
Ordinary
Purchase
100
4382
Ordinary
Purchase
200
4428
Ordinary
Purchase
100
4393
Ordinary
Purchase
100
4393
Ordinary
Purchase
100
4390
Ordinary
Purchase
400
4396
Ordinary
Purchase
200
4391
Ordinary
Purchase
600
4397
Ordinary
Purchase
600
4398
Ordinary
Purchase
100
4410
Ordinary
Purchase
200
4409
Ordinary
Purchase
1,100
4410
Ordinary
Purchase
400
4390
Ordinary
Purchase
5,600
4476
Ordinary
Sale
1,200
4404
Ordinary
Sale
100
4427
Ordinary
Sale
200
4419
Ordinary
Sale
200
4418
Ordinary
Sale
1,000
4407
Ordinary
Sale
500
4409
Ordinary
Sale
100
4411
Ordinary
Sale
500
4412
Ordinary
Sale
100
4417
Ordinary
Sale
300
4414
Ordinary
Sale
1,300
4413
Ordinary
Sale
500
4412
Ordinary
Sale
100
4415
Ordinary
Sale
100
4418
Ordinary
Sale
300
4400
Ordinary
Sale
100
4419
Ordinary
Sale
1,100
4420
Ordinary
Sale
100
4419
Ordinary
Sale
800
4421
Ordinary
Sale
800
4421
Ordinary
Sale
100
4409
Ordinary
Sale
800
4405
Ordinary
Sale
200
4408
Ordinary
Sale
600
4406
Ordinary
Sale
400
4406
Ordinary
Sale
200
4410
Ordinary
Sale
700
4410
Ordinary
Sale
600
4409
Ordinary
Sale
100
4415
Ordinary
Sale
1,000
4403
Ordinary
Sale
100
4401
Ordinary
Sale
900
4390
Ordinary
Sale
1,500
4414
Ordinary
Sale
100
4394
Ordinary
Sale
100
4391
Ordinary
Sale
200
4389
Ordinary
Sale
100
4464
Ordinary
Sale
10,000
4400
Ordinary
Sale
10,000
4397
Ordinary
Sale
10,000
4410
Ordinary
Sale
5,000
4420
Ordinary
Sale
5,000
4435
Ordinary
Sale
5,000
4445
Ordinary
Sale
100
4419.5
Ordinary
Sale
100
4408.5
Ordinary
Sale
5,400
4417.630322
Ordinary
Sale
1,100
4421
Ordinary
Sale
100
4419
Ordinary
Sale
100
4415
Ordinary
Sale
100
4406
Ordinary
Sale
200
4424
Ordinary
Sale
400
4396
Ordinary
Sale
600
4386
Ordinary
Sale
600
4395
Ordinary
Sale
600
4391
Ordinary
Sale
100
4426.5
Ordinary
Sale
600
4426.5
Ordinary
Sale
400
4426.5
Ordinary
Sale
700
4427
Ordinary
Sale
100
4434
Ordinary
Sale
100
4434
Ordinary
Sale
100
4434
Ordinary
Sale
400
4459.5
Ordinary
Sale
500
4459.5
Ordinary
Sale
200
4421
Ordinary
Sale
900
4419
Ordinary
Sale
400
4417.5
Ordinary
Sale
1,400
4465
Ordinary
Sale
100
4392
Ordinary
Sale
100
4390
Ordinary
Sale
100
4438
Ordinary
Sale
100
4407
Ordinary
Sale
100
4406
Ordinary
Sale
100
4402
Ordinary
Sale
100
4409
Ordinary
Sale
100
4410
Ordinary
Sale
100
4410
Ordinary
Sale
100
4407
Ordinary
Sale
100
4406
Ordinary
Sale
100
4414
Ordinary
Sale
100
4416
Ordinary
Sale
100
4413
Ordinary
Sale
100
4417
Ordinary
Sale
100
4419
Ordinary
Sale
100
4414
Ordinary
Sale
100
4405
Ordinary
Sale
100
4406
Ordinary
Sale
100
4405
Ordinary
Sale
100
4413
Ordinary
Sale
100
4406
Ordinary
Sale
100
4416
Ordinary
Sale
1,000
4370
Ordinary
Sale
1,100
4370
Ordinary
Sale
100
4393
Ordinary
Sale
100
4396
Ordinary
Sale
100
4391
Ordinary
Sale
100
4393
Ordinary
Sale
100
4443
Ordinary
Sale
1,100
4444
Ordinary
Sale
1,100
4424
Ordinary
Sale
200
4436
Ordinary
Sale
1,100
4425
Ordinary
Sale
600
4436
Ordinary
Sale
300
4426
Ordinary
Sale
200
4425
Ordinary
Sale
700
4455
Ordinary
Sale
1,100
4427
Ordinary
Sale
300
4429
Ordinary
Sale
500
4442
Ordinary
Sale
100
4421
Ordinary
Sale
1,100
4459
Ordinary
Sale
100
4420
Ordinary
Sale
100
4417
Ordinary
Sale
1,100
4464
Ordinary
Sale
700
4451
Ordinary
Sale
200
4430
Ordinary
Sale
200
4419
Ordinary
Sale
620
3957.3
Ordinary
Sale
5,600
4476
Total Purchases
60,700
Total Sales
99,320
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit JPY
Ordinary
CFD
Increasing a long position
31,700
4 406.173418
Ordinary
CFD
Increasing a long position
18,300
4 406.173418
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit JPY
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit JPY
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable) JPY
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
YES
Date of disclosure:
21/11/2018
Contact name:
Olivier Vero
Telephone number:
+44 20 7676 6969
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
1. KEY INFORMATION
Full name of person making disclosure:
SOCIETE GENERALE SA
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:
Takeda Pharmaceutical CO LTD
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of relevant security
Product description e.g. call option
Written or purchased
Number of securities to which option or derivative relates
Exercise price per unit
Type
Expiry date
JPY
e.g. American, European etc.
Ordinary
OTC put-option
Sale
15,700
4707
European options
14/12/2018
Ordinary
OTC put-option
Sale
30,000
5075.10
European options
14/12/2018
Ordinary
OTC put-option
Sale
29,600
5073.65
European options
14/12/2018
Ordinary
OTC put-option
Sale
15,500
4491.40
European options
14/12/2018
Ordinary
OTC put-option
Sale
30,700
4533.90
European options
14/12/2018
Ordinary
Listed call-option
Sale
125,000
5500
European options
13/06/2019
3. AGREEMENTS TO PURCHASE OR SELL ETC.
Full details should be given so that the nature of the interest or position can be fully understood:
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDRETPGGUAGUPRUBG
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement